Literature DB >> 15817189

Learned irrelevance is disrupted in first-episode but not chronic schizophrenia patients.

Gilad Gal1, Shlomo Mendlovic, Yuval Bloch, Gabriela Beitler, Yechiel Levkovitz, Andrew M J Young, Joram Feldon, Gideon Ratzoni.   

Abstract

Learned irrelevance (LIrr) is a pre-exposure effect in which uncorrelated presentations of a conditioned stimulus (CS) and an unconditioned stimulus (US) retard subsequent CS-US association. LIrr is closely related to the phenomenon of latent inhibition (LI). LI refers to the retarding effects of inconsequential stimulus pre-exposure on subsequent conditioning to that stimulus, and is considered to reflect the organism's capacity to ignore irrelevant stimuli. LI is disrupted in schizophrenia patients, due to faster learning of the association between the preexposed CS and the US. A new within-subject target-recognition LIrr procedure was applied. The target was either cued by a priming signal or appeared at random, and priming signals were novel or preexposed cues. Schizophrenia patients were compared to age- and sex-matched control subjects. Normal subjects (n = 24) have shown robust LIrr, namely, faster cue-target associations of novel compared to preexposed cues. Schizophrenia patients at the early stages of their first episode (n = 7) showed LIrr disruption, namely, cue-target associations to preexposed cues were as fast as for novel cues. Chronic patients during an acute phase (n = 18) did not show LIrr as they failed to learn the cue-target association. In addition to the LIrr paradigm the same subjects were tested in a covert-orientation task. No differences were observed between the groups on this task. The possible advantages of the new LIrr paradigm are discussed.

Entities:  

Mesh:

Year:  2005        PMID: 15817189     DOI: 10.1016/j.bbr.2004.11.017

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  8 in total

1.  Impaired contextual fear-conditioning in MAM rodent model of schizophrenia.

Authors:  Kathryn M Gill; Sarah A Miller; Anthony A Grace
Journal:  Schizophr Res       Date:  2017-09-18       Impact factor: 4.939

2.  Examining associations between psychosis risk, social anhedonia, and performance of striatum-related behavioral tasks.

Authors:  Nicole R Karcher; Elizabeth A Martin; John G Kerns
Journal:  J Abnorm Psychol       Date:  2015-08

3.  Learned irrelevance and associative learning is attenuated in individuals at risk for psychosis but not in asymptomatic first-degree relatives of schizophrenia patients: translational state markers of psychosis?

Authors:  Ariane T Orosz; Joram Feldon; Andor E Simon; Leonie M Hilti; Kerstin Gruber; Benjamin K Yee; Katja Cattapan-Ludewig
Journal:  Schizophr Bull       Date:  2010-01-15       Impact factor: 9.306

Review 4.  Memory-prediction errors and their consequences in schizophrenia.

Authors:  Michael S Kraus; Richard S E Keefe; Ranga K R Krishnan
Journal:  Neuropsychol Rev       Date:  2009-07-03       Impact factor: 7.444

5.  Cognitive functioning in the schizophrenia prodrome.

Authors:  Andor E Simon; Katja Cattapan-Ludewig; Solange Zmilacher; Dima Arbach; Kerstin Gruber; Diane N Dvorsky; Binia Roth; Emanuel Isler; Alexander Zimmer; Daniel Umbricht
Journal:  Schizophr Bull       Date:  2007-04-04       Impact factor: 9.306

6.  Human electrophysiological correlates of learned irrelevance: effects of the muscarinic M1 antagonist biperiden.

Authors:  Inge Klinkenberg; Arjan Blokland; Wim Riedel; Anke Sambeth
Journal:  Int J Neuropsychopharmacol       Date:  2011-11-18       Impact factor: 5.176

7.  Assessing the construct validity of aberrant salience.

Authors:  Kristin Schmidt; Jonathan P Roiser
Journal:  Front Behav Neurosci       Date:  2009-12-23       Impact factor: 3.558

8.  Are persistent delusions in schizophrenia associated with aberrant salience?

Authors:  Rafeef Abboud; Jonathan P Roiser; Hind Khalifeh; Sheila Ali; Isobel Harrison; Helen T Killaspy; Eileen M Joyce
Journal:  Schizophr Res Cogn       Date:  2016-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.